FENC Earnings

FENC reported its earnings on 2026-03-24, showcasing a revenue of 13.78M against an estimate of 14.97M, resulting in a -7.97% surprise. The EPS was -0.11, surpassing the expected 0.03 by -466.67%. The stock experienced a -19.19% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following FENC's earnings announcement on 2026-03-24, the stock price moved by -19.19% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, FENC's stock price tends to shift by an average of 5.3% in the 10 days leading up to earnings and 3.88% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate FENC's annual revenue to reach 17.48M, while the EPS is projected at 0.12. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between FENC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, FENC's stock price typically moves by 5.3% in the 10 days before its earnings and 3.88% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.12 and revenue of 17.48M.

The earnings call summary and Q&A section reveal a positive sentiment. Key highlights include the successful launch of PEDMARK in Europe and the U.K., significant expansion plans, and strong growth trends in the AYA patient segment. The field force expansion and the Fennec HEARS program are expected to drive sales growth. While financial guidance is pending, the anticipated revenue from partnerships and the resolution of litigation issues further bolster the outlook. The absence of unclear management responses also supports a positive sentiment.